{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Non-Hodgkin+Lymphoma&page=56", "query": { "condition": "B-Cell Non-Hodgkin Lymphoma", "page": 56 }, "page_size": 10 }, "pagination": { "page": 56, "page_size": 10, "total_count": 2217, "total_pages": 222, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Non-Hodgkin+Lymphoma&page=57&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Non-Hodgkin+Lymphoma&page=55&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T17:45:59.991Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00619645", "title": "Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 8, "start_date": "2007-06", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2018-01-10", "last_synced_at": "2026-10-19T17:45:59.991Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00619645" }, { "nct_id": "NCT04771572", "title": "Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Hodgkin Lymphoma", "Richter Transformation", "Multiple Myeloma", "T-cell-prolymphocytic Leukemia", "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Myeodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm", "Myelofibrosis", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Chronic Myelomonocytic Leukemia-2", "Myelodysplastic Neoplasm in Blast Phase" ], "interventions": [ { "name": "LP-118", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Newave Pharmaceutical Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 100, "start_date": "2022-05-08", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-19T17:45:59.991Z", "location_count": 8, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Chapel Hill, North Carolina + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04771572" }, { "nct_id": "NCT03287817", "title": "Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "AUTO3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Autolus Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2017-09-05", "completion_date": "2023-10-19", "has_results": true, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-10-19T17:45:59.991Z", "location_count": 7, "location_summary": "Duarte, California • Denver, Colorado • Miami, Florida + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03287817" }, { "nct_id": "NCT02663518", "title": "A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies", "Solid Tumor" ], "interventions": [ { "name": "PF-0791800 (TTI-621)", "type": "DRUG" }, { "name": "PF-07901800 (TTI-621) plus Rituximab", "type": "DRUG" }, { "name": "PF-07901800 (TTI-621) plus Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 249, "start_date": "2016-01-28", "completion_date": "2022-11-23", "has_results": true, "last_update_posted_date": "2024-05-10", "last_synced_at": "2026-10-19T17:45:59.991Z", "location_count": 47, "location_summary": "Duarte, California • Palo Alto, California • Denver, Colorado + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02663518" }, { "nct_id": "NCT06789159", "title": "A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B Cell Lymphoma Refractory", "Diffuse Large B Cell Lymphoma Relapsed", "Epstein-Barr Virus (EBV) Infection" ], "interventions": [ { "name": "VK-2019", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pierluigi Porcu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-08-21", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-19T17:45:59.991Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06789159" }, { "nct_id": "NCT01077518", "title": "Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Follicular" ], "interventions": [ { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Bendamustine infusion", "type": "DRUG" }, { "name": "Ofatumumab and Bendamustine infusions (Arm A)", "type": "DRUG" }, { "name": "Bendamustine infusion (Arm B)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 346, "start_date": "2010-08-26", "completion_date": "2018-12-26", "has_results": true, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-10-19T17:45:59.991Z", "location_count": 18, "location_summary": "Tucson, Arizona • Beverly Hills, California • Palm Springs, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01077518" }, { "nct_id": "NCT00004241", "title": "17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AIDS-related Peripheral/Systemic Lymphoma", "AIDS-related Primary CNS Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Chondrosarcoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Metastatic Osteosarcoma", "Nodal Marginal Zone B-cell Lymphoma", "Ovarian Sarcoma", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Osteosarcoma", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Uterine Sarcoma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult Soft Tissue Sarcoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "Stage IV Uterine Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-07", "last_synced_at": "2026-10-19T17:45:59.991Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004241" }, { "nct_id": "NCT03153202", "title": "Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joshua Brody", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 23, "start_date": "2017-07-14", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-10-19T17:45:59.991Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03153202" }, { "nct_id": "NCT06271369", "title": "Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 613, "start_date": "2022-08-11", "completion_date": "2023-02-15", "has_results": false, "last_update_posted_date": "2024-02-21", "last_synced_at": "2026-10-19T17:45:59.991Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06271369" }, { "nct_id": "NCT04312841", "title": "Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Prolymphocytic Leukemia", "Chronic Lymphocytic Leukemia", "Peripheral T-Cell Lymphoma", "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Sezary Syndrome", "T-Cell Prolymphocytic Leukemia" ], "interventions": [ { "name": "Letermovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-09-15", "completion_date": "2024-04-09", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-10-19T17:45:59.991Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04312841" } ] }